BIOCANCELL THERAPEUTICS INC. 4
4 · BIOCANCELL THERAPEUTICS INC. · Filed Aug 3, 2009
Insider Transaction Report
Form 4
BIOCANCELL THERAPEUTICS INC.BICL.TA
Ohana Patricia
VP of Clinical Development
Transactions
- Award
Employee Options
2008-12-03+56,966→ 220,000 totalExp: 2018-12-03→ Common Stock, par value $0.01 (56,966 underlying)
Footnotes (2)
- [F1]The exercise price is 1.27 NIS per share.
- [F2]4,382 options shall be exercisable at the end of each calendar quarter, from September 30, 2009 until September 30, 2012. The Reporting Person was granted the option on December 3, 2008, and reported the initial vested amount under the option on her Form 3 filed with the SEC on June 29, 2009. The Reporting Person is filing this Form 4 to report the remaining securities under the option.